Skip to main content
Explore URMC
menu

Colorectal Cancer: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Research Question:
Is adding the experimental drug, atezolizumab (MPDL3280A), to a usual treatment or giving the experimental drug alone better than the usual treatment alone and what are the good and bad effects of atezolizumab when added to the usual treatment and given alone?

Basic Study Information

Purpose:
This study has 3 study groups. A computer will, by chance assign you to one of the groups in the study. This is done because no one knows if one study group is worse or better than the others. You will have an equal chance of being in groups 1, 2, or 3. Group 1 will get FOLFOX and bevacizumab, Group 2 will get atezolizumab alone and Group 3 will receive FOLFOX and bevacizumab plus atezolizumab. The drugs will be given by infusion.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02997228?term=S1610&rank=1
Study Reference #: CGIC17133

Lead Researcher (Principal Investigator)

Lead Researcher: Marcus Noel

Study Contact Information

Study Coordinator: Tanya Smith
Phone: (585) 275-8213
Email: Tanya_Smith@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Colon Cancer

Return to Search